Profound Medical Corp.
PROF · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10,167 | $7,199 | $6,681 | $6,873 |
| % Growth | 41.2% | 7.8% | -2.8% | – |
| Cost of Goods Sold | $3,468 | $2,817 | $3,660 | $3,921 |
| Gross Profit | $6,699 | $4,382 | $3,021 | $2,952 |
| % Margin | 65.9% | 60.9% | 45.2% | 43% |
| R&D Expenses | $16,150 | $14,377 | $14,690 | $15,277 |
| G&A Expenses | $0 | $9,168 | $9,465 | $10,314 |
| SG&A Expenses | $22,023 | $18,621 | $17,933 | $17,966 |
| Sales & Mktg Exp. | $0 | $9,453 | $8,468 | $7,652 |
| Other Operating Expenses | $0 | $0 | $2,524 | $0 |
| Operating Expenses | $38,174 | $32,998 | $35,147 | $33,243 |
| Operating Income | -$31,475 | -$28,616 | -$32,126 | -$30,291 |
| % Margin | -309.6% | -397.5% | -480.9% | -440.7% |
| Other Income/Exp. Net | $4,992 | -$81 | $3,744 | -$303 |
| Pre-Tax Income | -$26,482 | -$28,697 | -$28,382 | -$30,594 |
| Tax Expense | -$2 | -$128 | $287 | $105 |
| Net Income | -$26,480 | -$28,569 | -$28,669 | -$30,699 |
| % Margin | -260.4% | -396.8% | -429.1% | -446.7% |
| EPS | -1.07 | -1.35 | -1.38 | -1.5 |
| % Growth | 20.7% | 2.2% | 8% | – |
| EPS Diluted | -1.07 | -1.35 | -1.38 | -1.5 |
| Weighted Avg Shares Out | 24,766 | 21,183 | 20,830 | 20,464 |
| Weighted Avg Shares Out Dil | 24,766 | 21,183 | 20,830 | 20,466 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,367 | $1,642 | $1,050 | $203 |
| Interest Expense | $0 | $770 | $167 | $66 |
| Depreciation & Amortization | $891 | $1,146 | $1,604 | $1,879 |
| EBITDA | -$25,591 | -$26,781 | -$26,604 | -$28,648 |
| % Margin | -251.7% | -372% | -398.2% | -416.8% |